Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Neuroepidemiology
|
June 17, 2010
Validation of a self-report comorbidity questionnaire for multiple sclerosis
Myles Horton, Richard A Rudick, Claire Hara-Cleaver, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 12, 2024
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial
Kunio Nakamura, Zhaonan Sun, Claire Hara-Cleaver, et al.
Journal of the Neurological Sciences
|
October 9, 2012
Early tolerability and safety of fingolimod in clinical practice
Daniel Ontaneda, Claire Hara-Cleaver, Richard A Rudick, et al.
JAMA Neurology
|
April 20, 2013
Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic
Edru Erbayat Altay, Elizabeth Fisher, Stephen E Jones, et al.
The International Journal of Neuroscience
|
October 2, 2014
Experience with fingolimod in clinical practice
Carrie M Hersh, Claire Hara-Cleaver, Richard A Rudick, et al.
Multiple Sclerosis and Related Disorders
|
December 7, 2016
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up
Carrie M Hersh, Thomas E Love, Samuel Cohn, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
September 12, 2017
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
Carrie M Hersh, Thomas E Love, Anasua Bandyopadhyay, et al.
Neurology. Clinical Practice
|
July 10, 2020
Technology-enabled assessments to enhance multiple sclerosis clinical care and research
Gabrielle Macaron, Brandon P Moss, Hong Li, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Neuroepidemiology
|
June 17, 2010
Validation of a self-report comorbidity questionnaire for multiple sclerosis
Myles Horton, Richard A Rudick, Claire Hara-Cleaver, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 12, 2024
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial
Kunio Nakamura, Zhaonan Sun, Claire Hara-Cleaver, et al.
Journal of the Neurological Sciences
|
October 9, 2012
Early tolerability and safety of fingolimod in clinical practice
Daniel Ontaneda, Claire Hara-Cleaver, Richard A Rudick, et al.
JAMA Neurology
|
April 20, 2013
Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic
Edru Erbayat Altay, Elizabeth Fisher, Stephen E Jones, et al.
The International Journal of Neuroscience
|
October 2, 2014
Experience with fingolimod in clinical practice
Carrie M Hersh, Claire Hara-Cleaver, Richard A Rudick, et al.
Multiple Sclerosis and Related Disorders
|
December 7, 2016
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up
Carrie M Hersh, Thomas E Love, Samuel Cohn, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
September 12, 2017
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
Carrie M Hersh, Thomas E Love, Anasua Bandyopadhyay, et al.
Neurology. Clinical Practice
|
July 10, 2020
Technology-enabled assessments to enhance multiple sclerosis clinical care and research
Gabrielle Macaron, Brandon P Moss, Hong Li, et al.
Page
of 1